BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 11773181)

  • 1. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.
    Motzer RJ; Bacik J; Murphy BA; Russo P; Mazumdar M
    J Clin Oncol; 2002 Jan; 20(1):289-96. PubMed ID: 11773181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma.
    Motzer RJ; Bacik J; Schwartz LH; Reuter V; Russo P; Marion S; Mazumdar M
    J Clin Oncol; 2004 Feb; 22(3):454-63. PubMed ID: 14752067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
    Motzer RJ; Mazumdar M; Bacik J; Berg W; Amsterdam A; Ferrara J
    J Clin Oncol; 1999 Aug; 17(8):2530-40. PubMed ID: 10561319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting survival of patients with metastatic renal cell carcinoma.
    Motzer RJ; Mazumdar M
    Urologe A; 2004 Sep; 43 Suppl 3():S135-6. PubMed ID: 15148574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.
    Hudes G; Carducci M; Tomczak P; Dutcher J; Figlin R; Kapoor A; Staroslawska E; Sosman J; McDermott D; Bodrogi I; Kovacevic Z; Lesovoy V; Schmidt-Wolf IG; Barbarash O; Gokmen E; O'Toole T; Lustgarten S; Moore L; Motzer RJ;
    N Engl J Med; 2007 May; 356(22):2271-81. PubMed ID: 17538086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
    Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
    Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasibility of prolonged use of interferon-alpha in metastatic kidney carcinoma: a phase II study.
    Kankuri M; Pelliniemi TT; Pyrhönen S; Nikkanen V; Helenius H; Salminen E
    Cancer; 2001 Aug; 92(4):761-7. PubMed ID: 11550145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for advanced renal cell cancer.
    Coppin C; Porzsolt F; Awa A; Kumpf J; Coldman A; Wilt T
    Cochrane Database Syst Rev; 2005 Jan; (1):CD001425. PubMed ID: 15674877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sunitinib in Patients With Metastatic Renal Cell Carcinoma: Clinical Outcome According to International Metastatic Renal Cell Carcinoma Database Consortium Risk Group.
    Rini BI; Hutson TE; Figlin RA; Lechuga MJ; Valota O; Serfass L; Rosbrook B; Motzer RJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):298-304. PubMed ID: 29853320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up.
    Minasian LM; Motzer RJ; Gluck L; Mazumdar M; Vlamis V; Krown SE
    J Clin Oncol; 1993 Jul; 11(7):1368-75. PubMed ID: 8315435
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study.
    Ko JJ; Xie W; Kroeger N; Lee JL; Rini BI; Knox JJ; Bjarnason GA; Srinivas S; Pal SK; Yuasa T; Smoragiewicz M; Donskov F; Kanesvaran R; Wood L; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Choueiri TK; Heng DY
    Lancet Oncol; 2015 Mar; 16(3):293-300. PubMed ID: 25681967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry.
    Wagstaff J; Jones R; Hawkins R; Porfiri E; Pickering L; Bahl A; Brown J; Buchan S
    Ann Oncol; 2016 Jan; 27(1):159-65. PubMed ID: 26489444
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic renal carcinoma comprehensive prognostic system.
    Atzpodien J; Royston P; Wandert T; Reitz M;
    Br J Cancer; 2003 Feb; 88(3):348-53. PubMed ID: 12569375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM; Figlin RA; Hutson TE; Michaelson MD; Kim ST; Baum CM; Kattan MW
    Cancer; 2008 Oct; 113(7):1552-8. PubMed ID: 18720362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using Interferon Alfa Before Tyrosine Kinase Inhibitors May Increase Survival in Patients With Metastatic Renal Cell Carcinoma: A Turkish Oncology Group (TOG) Study.
    Artaç M; Çoşkun HŞ; Korkmaz L; Koçer M; Turhal NS; Engin H; Dede İ; Paydaş S; Öksüzoğlu B; Bozcuk H; Demirkazık A
    Clin Genitourin Cancer; 2016 Aug; 14(4):e347-53. PubMed ID: 27236771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators.
    Lancet; 1999 Jan; 353(9146):14-7. PubMed ID: 10023944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
    Escudier B; Szczylik C; Hutson TE; Demkow T; Staehler M; Rolland F; Negrier S; Laferriere N; Scheuring UJ; Cella D; Shah S; Bukowski RM
    J Clin Oncol; 2009 Mar; 27(8):1280-9. PubMed ID: 19171708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.